
Dr. Nolan is the Rachford and Carlota A. Harris Professor in the Department of Microbiology and Immunology at Stanford University School of Medicine. He trained with Leonard Herzenberg (for his Ph.D.) and Nobelist Dr. David Baltimore (for postdoctoral work for the first cloning/characterization of NF-魏B p65/ RelA and the development of rapid retroviral production systems). He has published over 180 research articles and is the holder of 20 US patents, and has been honored as one of the top 25 inventors at Stanford University.
Dr. Nolan is the first recipient of the Teal Innovator Award (2012) from the Department of Defense (a $3.3 million grant for advanced studies in ovarian cancer), the first recipient of an FDA BAAA, for 鈥淏io-agent protection鈥 grant, $3million, from the FDA for a 鈥淐ross-Species Immune System Reference鈥, and received the award for 鈥淥utstanding Research Achievement in 2011鈥 from the Nature Publishing Group for his development of CyTOF applications in the immune system. Dr. Nolan has new efforts in the study of Ebola, having developed instrument platforms to deploy in the field in Africa to study Ebola samples safely with the need to transport them to overseas labs (funded by a new $3.5 million grant from the FDA).
His areas of research include hematopoiesis, cancer and leukemia, autoimmunity and inflammation, and computational approaches for network and systems immunology. Dr. Nolan鈥檚 recent efforts are focused on a single cell analysis advance using a mass spectrometry-flow cytometry hybrid device, the so- call 鈥淐yTOF鈥 and the 鈥淢ultiparameter Ion Beam Imager鈥 (MIBI) developed by Dr. Mike Angelo in his lab (Dr. Angelo is now an Assistant Professor in the Dept of Pathology at Stanford). The approaches uses an advanced ion plasma source to determine the levels of tagged reagents bound to cells鈥攅nabling a vast increase in the number of parameters that can be measured per cell鈥攅ither as flow cytometry devices (CyTOF) or imaging platforms for cancer (MIBI). Further efforts are being develop with another imaging platform terms CODEX that inexpensively converts fluorescence scopes to high dimensional imaging platforms.